Aptose Biosciences Inc. to Post Q3 2022 Earnings of ($0.12) Per Share, Oppenheimer Forecasts (NASDAQ:APTO)

Aptose Biosciences Inc. (NASDAQ:APTOGet Rating) (TSE:APS) – Stock analysts at Oppenheimer boosted their Q3 2022 EPS estimates for shares of Aptose Biosciences in a research report issued to clients and investors on Tuesday, August 2nd. Oppenheimer analyst M. Biegler now expects that the biotechnology company will post earnings of ($0.12) per share for the quarter, up from their previous forecast of ($0.13). The consensus estimate for Aptose Biosciences’ current full-year earnings is ($0.57) per share. Oppenheimer also issued estimates for Aptose Biosciences’ Q4 2022 earnings at ($0.11) EPS, FY2022 earnings at ($0.47) EPS, FY2023 earnings at ($0.48) EPS and FY2024 earnings at ($0.33) EPS.

Other equities research analysts have also issued research reports about the stock. StockNews.com upgraded shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, May 18th. Cantor Fitzgerald reduced their price target on shares of Aptose Biosciences from $10.00 to $6.00 in a report on Wednesday.

Aptose Biosciences Stock Performance

NASDAQ:APTO opened at $0.87 on Friday. Aptose Biosciences has a one year low of $0.71 and a one year high of $3.13. The firm has a market cap of $79.92 million, a P/E ratio of -1.38 and a beta of 1.52. The firm has a 50-day simple moving average of $0.84 and a 200-day simple moving average of $1.06.

Aptose Biosciences (NASDAQ:APTOGet Rating) (TSE:APS) last released its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. During the same quarter in the previous year, the firm earned ($0.18) earnings per share.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. WealthShield Partners LLC raised its stake in shares of Aptose Biosciences by 40.8% during the 4th quarter. WealthShield Partners LLC now owns 104,920 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 30,408 shares in the last quarter. Formidable Asset Management LLC bought a new position in shares of Aptose Biosciences during the 1st quarter worth approximately $122,000. Toronto Dominion Bank raised its stake in shares of Aptose Biosciences by 76.6% during the 1st quarter. Toronto Dominion Bank now owns 50,186 shares of the biotechnology company’s stock worth $68,000 after acquiring an additional 21,776 shares in the last quarter. Sigma Planning Corp raised its stake in shares of Aptose Biosciences by 39.5% during the 1st quarter. Sigma Planning Corp now owns 791,274 shares of the biotechnology company’s stock worth $1,076,000 after acquiring an additional 223,960 shares in the last quarter. Finally, Gleason Group Inc. acquired a new position in Aptose Biosciences during the 1st quarter valued at approximately $25,000. Institutional investors own 34.21% of the company’s stock.

Aptose Biosciences Company Profile

(Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Further Reading

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.